An automated pipeline for computation and analysis of functional ventilation and perfusion lung MRI with matrix pencil decomposition: TrueLung

Abstract

Purpose: To introduce and evaluate TrueLung, an automated pipeline for computation and analysis of free-breathing and contrast-agent free pulmonary functional MRI. Material and Methods: time-resolved ultra-fast bSSFP acquisitions are transferred to TrueLung, which includes image quality checks, image registration, and computation of perfusion and ventilation maps with matrix pencil decomposition. Neural network whole-lung and lobar segmentations allow quantification of impaired relative perfusion (RQ) and fractional ventilation (RFV). TrueLung delivers functional maps and quantitative outcomes, reported for clinicians in concise documents. We evaluated the pipeline in 75 cystic fibrosis children. Whole-lung and lobar segmentations were manually refined when necessary, and the impact on RQ and RFV was quantified. Results: Functional imaging was performed at 7.9 $\pm$ 1.8 (mean $\pm$ SD) coronal slice positions per patient, totaling on average 6min 20s scan time per patient. The whole pipeline required 20min calculation time per subject. TrueLung delivered the functional maps of all the subjects for radiological assessment. Quality controlling maps and segmentations lasted 1min 12s per patient. The automated segmentations and quantification of whole-lung defects were satisfying in 88% of patients (97% of slices) and the lobar quantification in 73% (93% of slices). The segmentations refinements required 16s per patient for the whole-lung, and 2min 10s for the lobe masks. The relative differences in RFV and RQ between fully-automated and manually refined data were marginal. Conclusions: TrueLung quickly delivers functional maps and quantitative outcomes in an objective and standardized way, suitable for radiological and pneumological assessment with minimal manual input. TrueLung can be used for clinical research in cystic fibrosis and might be applied across various lung diseases.